{"name":"Rein Therapeutics","slug":"rein-therapeutics","ticker":"","exchange":"","domain":"rein.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":11029000,"netIncome":-49871000,"cash":24158000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"date":"2026-03-26","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgJBVV95cUxOb2FpNnlvQ2NMX0ZSTnZkdGtFUXhFUzhyRXA4SjJQcF9uOHZRaWJDZ1hDUnZ0T0pLWmthYWRmM2NGTVNDZkFOQnZPbFlhY0lNUnJmNkpnYll3eERNOW8wVS1VMFV2QnE5bWMzZDBFcGduUUpqaDBpZGtSNlE1SDVDRTMxNENyMFJud3F0S3pyUi1rMHZhZ1JhUHNtc1VScWZoZkszc0lMYVFOaWhpUk5QMVhtbl92VU9WWlJnR2VwSnp5elhiV1hENHVXV0FpemhUa29jd0JxUGJqWnVFcTZ2dnAxWDQ4LTN4T3pyZ0xIcWtJdFk3dFVqaEp2cng2b0lSOTd0YTVQNGFXMzZteTA0N3VpbDg0U3dDT2J2QVliNGdPUldNa0Zndi1mRzZ3a3h1dHc?oc=5","date":"2026-02-09","type":"trial","source":"GlobeNewswire","summary":"Idiopathic Pulmonary Fibrosis Clinical Trials & Pipeline - GlobeNewswire","headline":"Idiopathic Pulmonary Fibrosis Clinical Trials & Pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxOUXQ2RkZLVVdUY1FXWE9oc1R2TngwSGtfb2NwRlFYUjliVm95UnZvN2x1WmxoS2JhRGZkcndVdWZmNTZXcnZFSkRtUjRsaDF4RTByT2xaLTJvME5vZTZtQXBHY2FuY1NTekFHdHBwS2FWUXNOd19GSVdnT1lGNGpNT0prWHBsN3c3cW5BSGFybkdHLTJMRzdxUmVwclBwbWM?oc=5","date":"2026-01-21","type":"trial","source":"The Clinical Trial Vanguard","summary":"Rein’s Breakthrough IPF Drug Gets Rare EU Orphan Status - The Clinical Trial Vanguard","headline":"Rein’s Breakthrough IPF Drug Gets Rare EU Orphan Status","sentiment":"positive"},{"date":"2026-01-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPdzduVzR5YzE1Mmh0YjYxMHBKY1lfb04zeGl6dFVudmdwUHh2cXFLQWM5Um5EMVM2blpJM2hzbjNFV0NIM190X29iczMteFJFVk9iMDlMb2prSGdLZWZpQ2NMRG5SOF9vdW84b0FoYXN3RHQ0UllVN3Z2NThCOTZkV3d2UlBtRmRsNDRTLTg1WVNnejdSWklnUUk3MnIyVHRaanR1TEhINGtmMjZPX2hwV05XM2RMeHlpcFJWOWVR?oc=5","date":"2025-12-11","type":"pipeline","source":"Fierce Pharma","summary":"Amgen obesity marketing leader Chris Boulton takes reins at metabolic biotech Prolynx - Fierce Pharma","headline":"Amgen obesity marketing leader Chris Boulton takes reins at metabolic biotech Prolynx","sentiment":"neutral"},{"date":"2025-12-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPSFZOV3dOalZhMTE4ZTNhNkVQMmZPZEI4OFNzQ1Y2dzBOcmJQMHdlRTBCb3pBcXFNSnktakIyZzhHUEVWQ2RReHhwWFkwYi1Rc0NEOENoQnRSNXROY3V2aXZNZ1g5UDVkUDV6Z0xmOFhZN0tFb0hlZGNGT0hjVVZXSXZpa3hoMDliYTc1eF9ycTZjMU1nMzNsNDlKYw?oc=5","date":"2025-11-18","type":"pipeline","source":"Pharma Voice","summary":"Amylin could reign supreme in the next wave of obesity drugs - Pharma Voice","headline":"Amylin could reign supreme in the next wave of obesity drugs","sentiment":"neutral"},{"date":"2025-11-14","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPanZxZlE1eS1xSEp5Q3ZORl9aejh1VWdsMGRsZGs4UjNBTUJOem83WXJIek0xOXRMS1hwd25mQjQ1czNsNlpya2MzamhIR25VazExRDNqZDIxV3hWR01IY3hhbDlzNG5BRldDOUZoY0RVdEVwQWo0M0l6RnFHeHFhRm1kMFdGbE91anJqYVpaSlRvV3YyUmJmTXpMN2lnc1gyMmxZSEpnMVpCYmZaX0JlVWVmQ1BXTXpPU19tQnJtUnk?oc=5","date":"2025-11-03","type":"trial","source":"Stock Titan","summary":"Rein Therapeutics (NASDAQ: RNTX) to resume Phase 2 IPF trial; U.S. enrollment at 20 sites - Stock Titan","headline":"Rein Therapeutics (NASDAQ: RNTX) to resume Phase 2 IPF trial; U.S. enrollment at 20 sites","sentiment":"neutral"},{"date":"2025-11-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-10-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-10-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-09-22","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":0,"period":"2017-12-31"},{"value":0,"period":"2016-12-31"},{"value":0,"period":"2015-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":11029000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-49871000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":24158000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}